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Abstract
Background: MicroRNAs (miRNAs) are a family of endogenous, small and noncoding RNAs that negatively regulate gene
expression by suppressing translation or degrading mRNAs. Recently, many studies investigated the association between
hsa-miR-196a2 rs11614913 polymorphism and cancer risk, which showed inconclusive results.
Methodology/Principal Findings: We conducted a meta-analysis of 15 studies that included 9,341 cancer cases and 10,569
case-free controls. We assessed the strength of the association, using odds ratios (ORs) with 95% confidence intervals (CIs).
Overall, individuals with the TC/CC genotypes were associated with higher cancer risk than those with the TT genotype
(OR=1.18, 95% CI=1.03–1.34, P,0.001 for heterogeneity test). In the stratified analyses, we observed that the CC genotype
might modulate breast cancer risk (OR=1.11, 95%CI=1.01–1.23, Pheterogeneity=0.210) and lung cancer risk (OR=1.25,
95%CI=1.06–1.46, Pheterogeneity=0.958), comparing with the TC/TT genotype. Moreover, a significantly increased risk was
found among Asian populations in a dominant model (TC/CC versus TT, OR=1.24, 95% CI=1.07–1.43, Pheterogeneity=0.006).
Conclusions: These findings supported that hsa-miR-196a2 rs11614913 polymorphism may contribute to the susceptibility
of cancers.
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Introduction
MicroRNAs (miRNAs) are a class of noncoding evolutionarily
conservedsmallRNAmoleculeswith ,22nucleotidesinlengththat
inhibit gene expression. Mature miRNAs operate via sequence-
specific interactions with the 3’ untranslated region (UTR) of
cognate mRNA targets, causing suppression of translation and
mRNA decay [1,2]. MiRNAs play important roles in the etiology of
many human diseases through post-transcriptionally regulating the
expression of approximately one third of all human genes [3].
At present, miRNAs have been involved in the etiology, progression
and prognosis of cancer [4]. In 2008, Hu et al. reported hsa-miR-196a2
might be a prognostic biomarker for non-small cell lung cancer [5].
Moreover, Pineau et al. found that the expression levels of some
miRNAs change gradually during the progression of liver disease and
miR-221 is capable of stimulating tumor growth possibility [6].
Single nucleotide polymorphisms (SNPs) occurring in miRNAs
are novel sources of genetic variation that may contribute to
cancer risk [7]. Recently, many studies research the association
between rs11614913 SNP in hsa-miR-196a2 and cancer suscep-
tibility, such as breast cancer [8–10], lung cancer [11,12],
hepatocellular carcinoma (HCC) [13,14], gastric cancer [15,16],
Esophageal Cancer (EC) [17,18] and others [19–2]. In addition,
Gao et al. performed a meta-analysis of hsa-miR-196a2, suggesting
that hsa-miR-196a2 rs11614913 polymorphism was associated
with an increased breast cancer risk [23].
However, the results of these studies remain conflicting rather than
conclusive. Considering the important role of hsa-miR-196a2
rs11614913 in the carcinogenic process, we performed a meta-
analysis on all eligible case-control studies to estimate the overall
cancer risk and to quantifythe potential between-study heterogeneity.
Materials and Methods
Literature search and data extraction
In order to identify the relative papers on hsa-miR-196a2
rs11614913 T.C polymorphism and cancer risk, we performed a
systematic search from PubMed and other studies in Public
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to English language papers, using the key words ‘miR-196a2’ or
‘rs11614913’, ‘polymorphism’ and ‘cancer’. In addition, studies
were identified by a manual search of the reference lists of reviews
and retrieved studies. If there were detailed allele frequency data
for the hsa-miR-196a2 polymorphism with cancer risk in a case-
control design, studies were selected. The data for this analysis
were available from 15 case-control studies, including 9,341 cases
with different types of cancers and 10,569 controls.
Two investigators independently extracted the data and reached
consensus on all items. The following information was sought from
each publication: the first author’s name, year of publication,
country of origin, ethnicity, cancer type, source of control
(population- or hospital-based controls), genotyping method and
number of cases and controls. For study including subjects of
different countries of origin group, we extracted data separately
[10]. Different ethnic descents were categorized as European,
Asian or mixed (composed of an admixture of different ethnic
groups). One study without detailed genotyping data was excluded
in the analyses [24].
Statistical analysis
The departure of frequencies of hsa-miR-196a2 polymorphism
from expectation under Hardy-Weinberg equilibrium (HWE) was
assessed by x
2 test in controls. The strength of the association
between the hsa-miR-196a2 polymorphism and cancer risk was
measured by odds ratios (ORs) with 95% confidence intervals (CIs).
Thestatisticalsignificanceofthe summaryORwasdeterminedwith
the Z-test. Pooled estimates of the OR were obtained by calculating
a weighted average of OR from each study. We first estimated the
risks of the variant genotype TC and CC, compared with the wild-
type TT homozygote, and then evaluated the risks of TC/CC
versus TT and CC versus TC/TT, assuming dominant and
recessive effects of the variant C allele, respectively. Stratified
analyses were also performed by cancer types (if one cancer type
contained one individual study, it was combined into other cancers
group), ethnicity and source of controls.
Statistical heterogeneity between studies was assessed with x
2
based Q test, and the heterogeneity was considered significant
when P,0.10 [25]. The fixed-effects model and the random-
effects model, based on the Mantel-Haenszel method and the
DerSimonian and Laird method, respectively, were used to pool
the data from different studies [26,27]. In the absence of
heterogeneity, these models provide similar results; otherwise,
the random-effects model is more appropriate. Sources of
heterogeneity were determined by using random-effects meta-
regression models with restricted maximum likelihood estimation.
The interstudy variance (t
2) was used to quantify the degree of
heterogeneity between studies, and the percentage of t
2 was used
to describe the extent of explained heterogeneity of the
characteristics [28].
Publication bias was evaluated with the funnel plot and the
linear regression asymmetry test by Egger et al [29]. P,0.10 was
used as an indication for the presence of potential publication bias.
All analyses were done with Stata software (version 8.2; StataCorp
LP, College Station, TX, USA), and all tests were two-sided.
Results
Characteristics of studies
There were 22 articles relevant to the search words and
manual search (Figure 1). Among these, 15 studies that included
a total of 9,341 cancer cases and 10,569 controls appeared to
meet the inclusion criteria and were subjected to further
examination. We excluded seven studies (four were not for
cancer research, one was review, one was case only study and
one did not report detailed allele frequency data). The selected
study characteristics are summarized in Table 1. All studies were
case-control studies, including four breast cancer studies, two
lung cancer studies, two gastric cancer studies, two HCC studies,
two esophageal cancer and the others were categorized into the
‘‘ther cancers’’group. Cancers were histologically or pathologi-
cally in most studies. There were nine studies of Asian descent,
six studies of European descent and one study of mixed ethnicity
Figure 1. Studies identified with criteria for inclusion and exclusion.
doi:10.1371/journal.pone.0018108.g001
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ment length polymorphism (PCR-RFLP) assay was conducted in
eight of the 15 studies (Table 1). The distribution of genotypes in
the controls was all in agreement with HWE for all except one
study (P=0.002) [21].
Quantitative synthesis
There was a variation in the C allele frequency of the hsa-miR-
196a2 rs11614913 T.C polymorphism among the controls across
different ethnicities, ranging from 0.42 to 0.75. For European
controls, the C allele frequency was 0.65 (95% CI=0.57–0.72),
which was higher than that in Asian controls (0.46, 95%CI=0.44–
0.49, P,0.001; Figure 2).
Overall, we observed the hsa-miR-196a2 rs11614913 polymor-
phism could increase the risk of cancer in all genetic models except
recessive model, when all the eligible studies were pooled into the
meta-analysis. As shown in Table 2, the TC heterozygote
(OR=1.16, 95% CI=1.02-1.32, Pheterogeneity=0.001) and variant
CC homozygote (OR=1.22, 95% CI=1.04–1.44, Pheterogeneity
,0.001) were associated with significantly increased risks of all
types of cancers compared with wild-type homozygote (TT).
Significant main effect was also observed in dominant model
(OR=1.18, 95% CI=1.03–1.34, Pheterogeneity ,0.001). However,
we did not observe the similar effect in recessive model
(OR=1.06, 95% CI=0.95–1.18, Pheterogeneity ,0.001; Table 2).
We then evaluated the effects of hsa-miR-196a2 rs11614913
T.C according to specific cancer types, different ethnicities and
different source of control. As show in Table 2, individuals
carrying the CC genotype could elevate breast cancer risk (CC
versus TT, OR=1.30, 95%CI=1.01–1.68, Pheterogeneity=0.028;
CC versus TC/TT, OR=1.11, 95% CI=1.01–1.23, Pheterogeneity
=0.210) and lung cancer risk (CC versus TT, OR=1.31, 95%
CI=1.09–1.58, Pheterogeneity=0.674; CC versus TC/TT,
OR=1.25, 95% CI=1.06-1.46, Pheterogeneity=0.958) compared
with those with TT or TC/TT genotypes. In addition, we found
that individuals with TC genotype had an increased risk of breast
cancer, comparing with TT genotype (OR=1.15, 95% CI=1.01–
1.31, P=0.162 for heterogeneity test). In recessive genetic model,
a significantly decreased risk was found for other cancers
(OR=0.81, 95% CI: 0.71–0.93, P=0.748 for heterogeneity test;
Table 2).
In the stratified analysis by ethnicity, significantly increased risks
were found in Asians (TC versus TT, OR=1.20, 95% CI=1.03–
1.39, Pheterogeneity=0.015; CC versus TT, OR=1.33, 95%
CI=1.09–1.62, Pheterogeneity=0.002; TC/CC versus TT,
OR=1.24, 95% CI=1.07–1.43, Pheterogeneity=0.006; CC versus
Table 1. Characteristics of literatures included in the meta-analysis.





Hu 2008 China Breast cancer Asian PCR-RFLP PB 1009/1093
Ye 2008 USA EC European SNPlex assay HB 307/338
Tian 2009 China Lung cancer Asian PCR-RFLP PB 1058/1035
Hoffman 2009 USA Breast cancer Mixed MassArray multiplex (sequenom) HB 426/466
Peng 2010 China Gastric cancer Asian PCR-RFLP HB 213/213
Qi 2010 China HCC Asian PCR–LDR HB 361/391
Dou 2010 China Glioma Asian PCR–LDR HB 643/656
Li 2010 China HCC Asian PCR-RFLP HB 310/222
Wang 2010 China EC Asian SNaPshot assay HB 458/489
Catucci 2010 Germany Breast cancer European Taqman HB 1101/1496
Italy Breast cancer European Taqman HB 751/1243
Srivastava 2010 India Gallbladder cancer European PCR-RFLP PB 230/230
George 2010 India Prostate cancer cancer European PCR-RFLP HB 159/230
Okubo 2010 Japan Gastric cancer Asian PCR-RFLP HB 552/697
Kim 2010 Korea Lung cancer Asian Fuorescence HB 654/640
Liu 2010 USA SCCHN European PCR-RFLP HB 1109/1130
EC: Esophageal Cancer; HCC: Hepatocellular Carcinoma; SCCHN: Squamous Cell Carcinoma of the Head and Neck; PCR-RFLP: Polymerase Chain Reaction-restriction
Fragment Length Polymorphism; PCR–LDR: Polymerase Chain Reaction–Ligation Detection Reaction; Fuorescence: Labeled Hybridization Probes; PB, Population Based;
HB, Hospital Based.
doi:10.1371/journal.pone.0018108.t001
Figure 2. Frequencies of the variant alleles (C allele) among
controls stratified by ethnicity. Black trangle m represents each
included study.
doi:10.1371/journal.pone.0018108.g002
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all genetic models tested. However, no significant association was
observed in Europeans (Table 2). According to source of controls,
significant effects were observed in both population-based studies
(TC/CC versus TT, OR=1.16, 95% CI=1.02–1.33, Pheterogeneity
=0.729) and hospital-based studies (TC/CC versus TT,
OR=1.19, 95% CI=1.01–1.40, Pheterogeneity ,0.001; Table 2).
Test of heterogeneity
Heterogeneity between studies was observed in overall com-
parisons and subgroup analyses. Then, we assessed the source of
heterogeneity for recessive model (CC versus TC/TT) by cancer
type, ethnicity and source of controls. As a result, cancer type
(x
2=22.55, df=5, P,0.001) and ethnicity (x
2=14.46, df=2,
P=0.001) but not source of controls (x
2=2.08, df=1, P=0.150)
were found to contribute to substantial heterogeneity. Further-
more, meta-regression analyses revealed that cancer type can
explain 25.5% (CC versus TC/TT, P=0.025) of the t
2.
Publication bias
Begger’s funnel plot and Egger’s test were performed to assess
the publication bias of included studies. As shown in Figure 3, the
shapes of the funnel plots did not reveal any evidence of obvious
asymmetry in all comparison models. Then, Egger’s test was used
to provide statistical evidence of funnel plot symmetry. The results
still did not show any evidence of publication bias (t=20.19,
P=0.853 for CC versus TC/TT).
Discussion
In the present study, hsa-miR-196a2 rs11614913 T.C poly-
morphism was found to be associated with an significantly increased
cancer risk in the variant TC heterozygote, CC homozygote, and
TC/CC genotype as opposed to the TT wild-type homozygote,
including 9,034 cancer cases and 10,231 controls.
The biogenesis of miRNAs is related to a complex protein
system, such as dicer and drosha [30]. MiRNAs participate in
crucial biological process, including development, differentiation,
apoptosis and proliferation [31,32]. Genetic variations in the
miRNA genes could potentially influence the processing or target
selection of miRNAs [33]. Recently, Ryan et al. conducted a
review about genetic variation in miRNA for the cancer research,
suggesting that the variations in miRNA might be related to the
risk of cancer [34]. Tian et al. observations suggested that hsa-miR-
196a2 rs11614913 polymorphism could contribute to the risk of
lung cancer [11]. Hu et al. thought that rs11614913 polymorphism
might be a prognostic biomarker for lung cancer [5]. Interestingly,
in 2010, so far there had been eleven published studies about the
association between hsa-miR-196a2 rs11614913 polymorphism
and cancer risk. Hsa-miR-196a2 may be a hot concern to predict
cancer susceptibility. Given the important role of that rs11614913
polymorphism locating in the hsa-miR-196a2 39 mature sequence
affects the maturation and effect of target mRNA possibility [34],
it is biologically plausible that genetic variation of hsa-miR-196a2
may modulate cancer susceptibility.
Consistent with Gao et al observations, our results showed that
the CC genotype may increase breast cancer risk in a C allele
dose-response manner [23]. Hu et al. showed that expression levels
of mature of hsa-mir-196a2 were increased in rs11614913 CC in
the human lung cancer tissues and binding assays revealed that the
rs11614913 could affect binding of mature hsa-miR-196a2 to its
target mRNA [5]. Moreover, we also found that individuals
carrying CC genotype might increase lung cancer susceptibility.
However, the similar association was not observed in HCC, gastric
cancer and EC patients. One factor that would contribute to the
discrepancy between different studies is that this polymorphism
might play a different role in different cancer sites. Landgraf et al.
found that 3p hsa-miR-196a2 was detectable in the MCF-7 breast
adenocarcinoma cell line [35]. Hu et al. reported that hsa-miR-
196a2 rs11614913 T.C located in hsa-mir-196a29 3p mature
Table 2. Meta-analysis for the hsa-miR-196a2 rs11614913 polymorphism and cancer risk.
Variables na TC versus TT CC versus TT TC/CC versus TT (dominant) CC versus TC/TT (recessive)
OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b
Total 16 1.16 (1.02–1.32) 0.001 1.22 (1.04–1.44) ,0.001 1.18 (1.03–1.34) ,0.001 1.06 (0.95–1.18) ,0.001
Cancer types
Breast cancer 4 1.15 (1.01–1.31) 0.162 1.30 (1.01–1.68) 0.028 1.22 (1.00–1.50) 0.062 1.11 (1.01–1.23) 0.210
Lung cancer 2 1.08 (0.92–1.27) 0.493 1.31 (1.09–1.58) 0.674 1.15 (0.99–1.34) 0.470 1.25 (1.06–1.46) 0.958
Gastric cancer 2 1.07 (0.85–1.34) 0.848 1.25 (0.94–1.65) 0.306 1.12 (0.90–1.39) 0.698 1.22 (0.97–1.55) 0.162
HCC 2 1.10 (0.85–1.43) 0.125 1.25 (0.65–2.39) 0.040 1.17 (0.72–1.89) 0.051 1.13 (0.87–1.46) 0.137
EC 2 1.19 (0.29–4.81) ,0.001 1.22 (0.26–5.72) ,0.001 1.20 (0.28–5.11) ,0.001 1.05 (0.63–1.74) 0.021
Other cancers 4 1.14 (1.06–1.22) 0.391 0.94 (0.78–1.12) 0.744 1.09 (0.93–1.27) 0.625 0.81 (0.71–0.93) 0.322
Ethnicities
Asian 9 1.20 (1.03–1.39) 0.015 1.33 (1.09–1.62) 0.002 1.24 (1.07–1.43) 0.006 1.17 (1.02–1.34) 0.037
European 6 1.01 (0.81–1.28) 0.040 0.97 (0.85–1.12) 0.121 0.98 (0.79–1.22) 0.046 0.91 (0.79–1.03) 0.099
Mixed 1 1.80 (1.16–2.80) - 2.15 (1.37–3.38) - 1.95 (1.27–2.98) - 1.34 (1.02–1.75) -
Source of controls
Population-based 3 1.11 (0.97–1.28) 0.503 1.30 (1.10–1.54) 0.743 1.16 (1.02–1.33) 0.729 1.09 (0.84–1.42) 0.038
Hospital-based 13 1.17 (1.00–1.38) ,0.001 1.22 (0.99–1.49) ,0.001 1.19 (1.01–1.40) ,0.001 1.05 (0.93–1.18) 0.002
aNumber of comparisons.
bP value of Q-test for heterogeneity test. Random-effects model was used when P value for heterogeneity test ,0.10; otherwise, fix-effects model was used.
HCC: hepatocellular carcinoma; EC: Esophageal Cancer.
doi:10.1371/journal.pone.0018108.t002
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cancer [9]. In addition, rs11614913 T.C was shown to be
associated with lung cancer risk, through altering the expression of
mature miR-196a and binding activity of target mRNA [5]. We
observed that there was a significantly decreased risk of other
cancers in the recessive model. Although the exact mechanism for
this inverse association was not clear, carcinogenic mechanisms
may differ for different tumor sites and the hsa-miR-196a2 genetic
variants may exert varying effects in different cancers. In addition,
other cancers is composed of four different tumor studies.
Therefore, the results should be interpreted with caution.
In population level, we found that individuals with variant C
allele could increase cancer susceptibility in Asians but not in
Europeans, suggesting a possible role of ethnic differences in
genetic background and the environment they lived in [36]. When
stratifying the source of control, significant associations were
observed in hospital-based and population-based controls. This
may result from most of the included studies matching age, sex
and residential area and sample size .500 to control selection
bias.
To identify the source of heterogeneity, we stratified the studies
according to ethnicity, cancer type and source of control. We
found the sources of heterogeneity were from ethnicity and cancer
type, suggesting population and cancer specific playing important
roles.
One of the strengths of our meta-analysis was that numbers of
cases and controls were pooled from each included studies, which
significantly increased the statistical power. Second, according our
selection criteria, the quality of studies included in our meta-
analysis was satisfactory. Third, furthermore, on the basis of our
study, functional variants of hsa-miR-196a2 might be conducted
and replicate these observations, so that it might find a novel
mechanism to predict the risk of cancer. Some limitations exist in
our meta-analysis. First, we pooled the data based on unadjusted
information, while a more precise analysis needs to be conducted if
individual data are available. Second, lacking the origin data of
including studies limited the further evaluation of the potential
interactions, because gene-environment interactions may modu-
late the cancer susceptibility. Third, studies published in English
were included and selection bias could have occurred.
In conclusion, our meta-analysis suggested that the hsa-miR-
196a2 rs11614913 polymorphism may contribute to genetic
susceptibility for increased cancer risk. We observed the similar
association in Asian populations but not in Europeans. Future
larger population and functional study should be performed to
validate these results and need to replicate in Africans.
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